Theseus Pharmaceuticals (Theseus Pharmaceuticals) Total Assets : $234.63 Mil (As of Sep. 2023)

View and export this data going back to 2021. Start your Free Trial

What is Theseus Pharmaceuticals Total Assets?

Theseus Pharmaceuticals's Total Assets for the quarter that ended in Sep. 2023 was $234.63 Mil.

During the past 12 months, Theseus Pharmaceuticals's average Total Assets Growth Rate was 65.20% per year. During the past 3 years, the average Total Assets Growth Rate was 505.90% per year.

During the past 4 years, Theseus Pharmaceuticals's highest 3-Year average Total Assets Growth Rate was 505.90%. The lowest was 505.90%. And the median was 505.90%.

Total Assets is connected with ROA %. Theseus Pharmaceuticals's annualized ROA % for the quarter that ended in Sep. 2023 was -22.52%. Total Assets is also linked to Revenue through Asset Turnover. Theseus Pharmaceuticals's Asset Turnover for the quarter that ended in Sep. 2023 was 0.00.

Theseus Pharmaceuticals Total Assets Historical Data

The historical data trend for Theseus Pharmaceuticals's Total Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Theseus Pharmaceuticals Total Assets Chart

Theseus Pharmaceuticals Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Total Assets

1.43

8.61

250.93

222.45

Theseus Pharmaceuticals Quarterly Data
	Dec19	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23
Total Assets	Get a 7-Day Free Trial										230.29	222.45	255.62	245.07	234.63

Theseus Pharmaceuticals Total Assets Calculation

Total Assets are all the assets a company owns.

From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.

Theseus Pharmaceuticals's Total Assets for the fiscal year that ended in Dec. 2022 is calculated as

Total Assets	=	Total Equity (A: Dec. 2022 )	+	Total Liabilities (A: Dec. 2022 )
	=	207.615	+	14.832
	=	222.45

Theseus Pharmaceuticals's Total Assets for the quarter that ended in Sep. 2023 is calculated as

Total Assets	=	Total Equity (Q: Sep. 2023 )	+	Total Liabilities (Q: Sep. 2023 )
	=	224.522	+	10.105
	=	234.63

Theseus Pharmaceuticals (NAS:THRX) Total Assets Explanation

Total Assets is connected with ROA %.

Theseus Pharmaceuticals's annualized ROA % for the quarter that ended in Sep. 2023 is

ROA %	=	Net Income (Q: Sep. 2023 )	/	( (Total Assets (Q: Jun. 2023 )	+	Total Assets (Q: Sep. 2023 ))	/ count )
	=	-54.016	/	( (245.071	+	234.627)	/ 2 )
	=	-54.016	/	239.849
	=	-22.52 %

Note: The Net Income data used here is four times the quarterly (Sep. 2023) data.

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Total Assets is linked to total revenue through Asset Turnover.

Theseus Pharmaceuticals's Asset Turnover for the quarter that ended in Sep. 2023 is

	Asset Turnover
=	Revenue (Q: Sep. 2023 )	/	( (Total Assets (Q: Jun. 2023 )	+	Total Assets (Q: Sep. 2023 ))	/ count )
=	0	/	( (245.071	+	234.627)	/ 2 )
=	0	/	239.849
=	0.00

Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.

Theseus Pharmaceuticals Total Assets Related Terms

Thank you for viewing the detailed overview of Theseus Pharmaceuticals's Total Assets provided by GuruFocus.com. Please click on the following links to see related term pages.

Theseus Pharmaceuticals (Theseus Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Theseus Pharmaceuticals Inc (NAS:THRX) » Definitions » Total Assets

Comparable Companies

Traded in Other Exchanges

N/A

Address

245 Main Street, Cambridge, MA, USA, 02142

Website

https://www.theseusrx.com

Theseus Pharmaceuticals Inc is a biopharmaceutical company focused on improving the lives of cancer patients through the discovery, development and commercialization of transformative targeted therapies. The company's development programs are designed to address drug resistance mutations in key driver oncogenes, which are mutated genes that cause cancer.

Executives

Orbimed Advisors Llc	director, 10 percent owner	601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Carl L Gordon	director, 10 percent owner	601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Foresite Capital Fund V, L.p.	10 percent owner	600 MONTGOMERY STREET, SUITE 4500, SAN FRANCISCO CA 94111
Hayden Donald J Jr	director	C/O AMICUS THERAPEUTICS, INC., 1 CEDAR BROOK DRIVE, CRANBURY NJ 08512
Bradford D. Dahms	officer: Chief Financial Officer	C/O SELECTA BIOSCIENCES, INC., 480 ARSENAL WAY, WATERTOWN MA 02472
Timothy P Clackson	director, officer: President and CEO	C/O ARIAD PHARMACEUTICALS INC, 26 LANDSDOWNE STREET, CAMBRIDGE MA 02139
Steven H Stein	director	1801 AUGUSTINE CUT-OFF, WILMINGTON DE 19803
Foresite Capital Opportunity Management V, Llc	10 percent owner	900 LARKSPUR LANDING CIRCLE, SUITE 150, LARKSPUR CA 94939
Foresite Capital Opportunity Fund V, L.p.	10 percent owner	600 MONTGOMERY STREET, SUITE 4500, SAN FRANCISCO CA 94111
Foresite Capital Management V, Llc	10 percent owner	900 LARKSPUR LANDING CIRCLE, SUITE 150, LARKSPUR CA 94939
James B. Tananbaum	10 percent owner	3052 PACIFIC AVENUE, SAN FRANCISCO CA 94115
William Shakespeare	officer: See Remarks	245 MAIN STREET, 2ND FLOOR, CAMBRIDGE MA 02142
Rock Springs Capital Master Fund Lp	10 percent owner	190 ELGIN AVENUE, GEORGE TOWN E9 KY1 9001
Omega Fund Vi Gp Manager, Ltd.	10 percent owner	888 BOYLSTON STREET, SUITE 1111, BOSTON MA 02199
Orbimed Capital Gp Vii Llc	10 percent owner	601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022